OBJECTIVE: Rheumatoid arthritis (RA) patients have a greater depressive tendency than normal subjects, and infliximab is known to provide quick therapeutic effects and to have high bioavailability for RA. We therefore investigated whether the depressive state of RA patients would be improved by infliximab. MATERIAL AND METHODS: The Self-Rating Depression Scale (SDS) was used to evaluate 34 RA patients before and 14 or 30 weeks after inflixi mab treatment using the SDS and Disease Activity Score (DAS) 28. The SDS and DAS28 results before and after treatment were compared. RESULTS: We also included 42 cases treated with methotrexate as the control group. The SDS decreased in both groups, and the intraindividual vari ability was p<0.001, indicating that the drugs had significantly different effects on the SDS. The DAS tended to decrease in both groups, but the intraindividual variability was p=0.199, indicating no difference between the two drugs. CONCLUSION: This study is a preliminary study, but the data suggest that infliximab may reduce RA disease activity and improve the depressive state.
OBJECTIVE:Rheumatoid arthritis (RA) patients have a greater depressive tendency than normal subjects, and infliximab is known to provide quick therapeutic effects and to have high bioavailability for RA. We therefore investigated whether the depressive state of RApatients would be improved by infliximab. MATERIAL AND METHODS: The Self-Rating Depression Scale (SDS) was used to evaluate 34 RApatients before and 14 or 30 weeks after inflixi mab treatment using the SDS and Disease Activity Score (DAS) 28. The SDS and DAS28 results before and after treatment were compared. RESULTS: We also included 42 cases treated with methotrexate as the control group. The SDS decreased in both groups, and the intraindividual vari ability was p<0.001, indicating that the drugs had significantly different effects on the SDS. The DAS tended to decrease in both groups, but the intraindividual variability was p=0.199, indicating no difference between the two drugs. CONCLUSION: This study is a preliminary study, but the data suggest that infliximab may reduce RA disease activity and improve the depressive state.
Authors: P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245
Authors: Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans Journal: Arthritis Rheum Date: 2005-11
Authors: T J Fabian; M A Dew; B G Pollock; C F Reynolds; B H Mulsant; M A Butters; M D Zmuda; A M Linares; M Trottini; P D Kroboth Journal: Biol Psychiatry Date: 2001-11-15 Impact factor: 13.382
Authors: Y Miwa; N Yajima; F Shiozawa; Y Yoda; R Hanaoka; M Hanyuda; M Hosaka; T Kasama; M Negishi; H Ide; M Adachi Journal: Mod Rheumatol Date: 2002-03 Impact factor: 3.023
Authors: Flavia del Porto; Luigi Aloe; Bruno Laganà; Viviana Triaca; Italo Nofroni; Raffaele D'Amelio Journal: Ann N Y Acad Sci Date: 2006-06 Impact factor: 5.691
Authors: Brenda W J H Penninx; Stephen B Kritchevsky; Kristine Yaffe; Anne B Newman; Eleanor M Simonsick; Susan Rubin; Luigi Ferrucci; Tamara Harris; Marco Pahor Journal: Biol Psychiatry Date: 2003-09-01 Impact factor: 13.382
Authors: Marcus A Gray; Che-Yung Chao; Heidi M Staudacher; Natasha A Kolosky; Nicholas J Talley; Gerald Holtmann Journal: PLoS One Date: 2018-03-08 Impact factor: 3.240